AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03268382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: Intravenous infusion
Study NCT03268382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Description: Intravenous infusion
Study NCT03821714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid combination therapy
Description: Glucocorticoid combination therapy is defined as the combination of hydrocortisone, vitamin C, and vitamin B1.
Study NCT03821714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid
Description: The glucocorticoid group was defined as the use of hydrocortisone alone.
Study NCT02782065 — intervention group
Intervention type: OTHER
Intervention: Not an interventional study
Study NCT00489086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tazarotene
Description: Tazarotene is a member of the acetylenic class of retinoids.
Study NCT02291601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: comparison with other CHG products
Study NCT02291601 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Excipients of CHG product only.
Study NCT03351738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
Study NCT03213990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuous infusion
Description: Clinician prescribed beta-lactam antibiotic will be administered via continuous infusion for as long as prescribed whilst in the ICU
Study NCT03213990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intermittent infusion
Description: Clinician prescribed beta-lactam antibiotic will be administered via intermittent infusion for as long as prescribed whilst in the ICU
Study NCT02322541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garlic Intervention
Description: Participants will consume an Allium-free controlled diet for 3 days. On the 4th day, they will consume a test meal containing garlic followed by blood and urine collections for 10 hours. On the 5th day, participants will have a fasting blood and urine collection.
Study NCT02291601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DynaHex-2
Description: 2% CHG solution
Study NCT02260128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: The intervention group will receive chewing gum four times daily following surgery.
Study NCT03149133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy hypertrophy training
Description: Training with 75-80 % of 1-RM
Study NCT03149133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light hypertrophy training
Description: Training with 35-50 % of 1-RM
Study NCT03116555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
Study NCT03116555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was used as second line treatment with AGC
Study NCT04123535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
Description: The ExAblate 2100 MRgFUS system (InSightec, Inc., Dallas, Texas, USA) is a noninvasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.14-16 The ExAblate combines a focused ultrasound surgery (FUS) delivery system and a conventional diagnostic 3T Magnetic Resonance (MR) scanner. The ExAblate systems provide a real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control. The ExAblate transducer device is an integrated component of the MR table
Study NCT02141412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 0.25 µg/kg IV
Study NCT02141412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 0.5 µg/kg IV
Study NCT02141412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 1 µg/kg IV
Study NCT02141412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
Study NCT03998683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Description: Guselkumab 100 mg will be administered as SC injection.
Study NCT03998683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guselkumab 100 mg
Description: Guselkumab 100 mg will be administered as SC injection.
Study NCT03998683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC injection.
Study NCT03998683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as SC injection.
Study NCT03266822 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational study
Study NCT00767728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulated mesalamine
Description: 0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning.
Study NCT00767728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules (4 capsules) were administered orally QD, in the morning.
Study NCT00435487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin ( Fragmin)
Description: Dalteparin will be administered at a dose of 120 IU/kg (international units per kilogram) total body weight subcutaneously (SC) every 12 hours up to a maximum dose of 10,000 IU/12 hours.
Study NCT00435487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Unfractionated heparin will be given intravenously according to a weight-adjusted nomogram (bolus of 60 U/kg \[units per kilogram\] and initial infusion of 12 U/kg/h \[units per kilogram per hour\]).
Study NCT03483961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/unadjuvanted
Description: Vaccine consists of virus-like particles of chikungunya virus antigens
Study NCT03483961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvanted
Description: Adjuvanted formulation includes Alhydrogel
Study NCT03355430 — intervention group
Intervention type: PROCEDURE
Intervention: combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK)
Description: After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
Study NCT03355430 — intervention group
Intervention type: PROCEDURE
Intervention: accelerated corneal collagen cross-linking (CXL)
Description: After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
Study NCT00634816 — intervention group
Intervention type: RADIATION
Intervention: DXA Scan
Description: The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion. Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
Study NCT03483961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is vaccine diluent alone
Study NCT02484001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL 800 mg
Description: one (1) tablet of 800 mg (QD).
Study NCT02484001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL 1200 mg
Description: one (1) and a half tablets of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
Study NCT02484001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL 1600 mg
Description: two (2) tablets of 800 mg (QD).
Study NCT02484001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL 400 mg
Description: half tablet of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
Study NCT01698242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Training
Description: PCP-Level: A PCP randomized to the Enhanced Training (ET) group will receive: 1) a full and pocket sized copy of the current AHA Heart Failure (HF) Guidelines; 2) a summary of their patient's data collected at baseline, 6-month, and 30-month in-person study visits; and 3) an invitation to complete the CHART-designed online course in HF management for CME credit.~Patient Level: The ET patient-level intervention uses Community Health Workers (CHWs) to assist the patient in learning self-management behaviors to reduce the risk of hospitalization. The key objectives are to: improve heart failure knowledge; encourage use of HF management tools; and facilitate development of self-management skills. Each participant receives at least: six AHA educational mailings, six monthly home visits, and 18 phone calls by CHWs within the first six months of the intervention. The CHW then conducts monthly telephone visits for the subsequent two years (for a total of 30 months of follow-up).
Study NCT03798600 — intervention group
Intervention type: DRUG
Intervention: Caspofungin
Description: In accordance with routine clinical practice, Caspofungin will be given at the loading dose of 70 mg followed by 50 mg daily (for people \< 80 kg body weight). No dose reduction will be performed in Child-Pugh score A or B. Duration of therapy will be performed in accordance with ESCMID guidelines and clinical conditions.
Study NCT01698242 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Education
Description: The Enhanced Education (EE) intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention provides nominal information through the mail. Randomization occurs at the PCP-level; patients are assigned to the EE group only if their PCP already has been randomized to this group.~PCP Level: Upon randomization to the EE group each PCP will receive a full-sized copy of the current American Heart Association (AHA) Heart Failure Guidelines within thirty days after randomization.~Patient Level: Upon their assignment to the EE group, patients will receive: Six AHA Tip-Sheet mailings (one Tip-Sheet to be mailed each of the first six months following group assignment); a telephone call, made by the CHART Research Assistant (RA), completed once during each of the first six months following group assignment and only to confirm that the patient received the Tip-Sheet mailing for that month.
Study NCT03209622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy delivred in cardiology intensive care unit versus Nicotine replacement therapy delivered after hospital discharge
Description: when patient is admitted in intensive care of cardiology for acute coronary syndrome he is randomized to Arm A or Arm B
Study NCT04241692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CarnationTM Ambulatory Monitoring Sternal ECG Patch System
Description: A newly developed cardiac rhythm monitoring system
Study NCT04241692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional 24-Hour 7 Lead Holter Monitor Recorder
Description: Traditional recordings made using a standard 24-hour Holter monitor.
Study NCT03209622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy delivred in cardiology intensive care unit versus Nicotine replacement therapy delivered after hospital discharge
Description: when patient is admitted in intensive care of cardiology for acute coronary syndrome he is randomized to Arm A or Arm B
Study NCT03209622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Arm A
Study NCT03209622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the external consultation
Description: without patch
Study NCT03572816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Settner shoe
Description: custom-made heel-unloading orthosis ('Settner shoe') in aftercare of calcaneus fractures (used according to manufacturer), certified 'CE' product with more than 10 years experience
Study NCT00519428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: 10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted
Study NCT00519428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion extra long (XL)
Description: 150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted
Study NCT00519428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram + bupropion
Description: same dosing schedule as for monotherapy
Study NCT03119753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Prototyping method of fabrication of complete denture
Description: For Rapid Prototyping Method of fabrication of complete denture : the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
Study NCT03119753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method of fabrication of complete denture
Description: For Conventional Method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
Study NCT01579838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: PNH and or atypical TTP classical protocols
Study NCT01940900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E10030
Study NCT01940900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT01940900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Study NCT02081235 — intervention group
Intervention type: PROCEDURE
Intervention: surgery for congenital heart disease
Description: surgery for congenital heart disease
Study NCT03723343 — intervention group
Intervention type: DRUG
Intervention: GP+IMRT
Description: Gemcitabine 1000 mg/m2 intravenously, d1\&d8 +Cisplatin 80 mg/m2 intravenously, d1 21\~28 days/cycle, 4 patients with oligometastasis, 6 cycles with multiple metastases
Study NCT03723343 — intervention group
Intervention type: DRUG
Intervention: TPF+IMRT
Description: Docetaxel: 75mg/m2 intravenous drip, d1+Cisplatin75mg/m2 intravenous drip, d1\~d5+5-fluorouracil 750mg/m2/d intravenous drip, d1\~d521\~28 days/cycle, patients with oligometastasis take 4 cycles, moreTransfer patients for 6 cycles
Study NCT00642837 — intervention group
Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Osteoarthritis, flexible dose depending on patients' pain relief
Study NCT00642837 — intervention group
Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Post surgical neurophatic pain, flexible dose depending on patients' pain relief
Study NCT00642837 — intervention group
Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Post traumatic neuropathic pain, flexible dose depending on patient pain relief
Study NCT00642837 — intervention group
Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Spinal Cord Injury, flexible dose depending on patients' pain relief
Study NCT00642837 — intervention group
Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief
Study NCT00642837 — intervention group
Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Diabetic Neuropathy, flexible dose depending on patients' pain relief
Study NCT00642837 — intervention group
Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Post stroke pain, flexible dose depending on patients' pain relief
Study NCT00642837 — intervention group
Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Low back pain, flexible dose depending on patients' pain relief
Study NCT00642837 — intervention group
Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Post Herpetic Neuralgia, flexible dose depending on patients' pain relief
Study NCT00642837 — intervention group
Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief
Study NCT03989947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Description: Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
Study NCT01163890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work and Health Initiative
Description: Telephone-based multi-modal intervention, consisting of: vocational coaching, cognitive-behavioral therapy strategies and care coordination strategies provided by specially-trained EAP counselors
Study NCT01163890 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Medical or Behavioral Intervention
Description: Referral to treatment as usual through personal physician, mental health professional, behavioral health program, and/or Employee Assistance Program
Study NCT01940900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E10030 sham intravitreal injection
Description: Pressure on the eye with a syringe with no needle
Study NCT04688086 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thermalytix
Description: Thermalytix is an Artificial intelligence based automated breast screening solution that analyzes thermal distribution on the breast to generate a breast health score automatically. Thermal imaging was performed by a trained technician to capture thermal images of the participant in five views. These thermal images were uploaded to Thermalytix software on the cloud where it was automatically analyzed by AI-based Thermalytix computer-aided detection (CADe) engine. This CADe engine analyzes uploaded thermal images and outputs an interpretation report for each participant with quantitative scores corresponding to computed probability of malignancy based on the structural, vascular, areolar, thermal properties of the observed abnormality. Thermalytix also generates annotated images with markings of abnormal regions and an overall Thermalytix score suggesting likelihood of breast malignancy. The locked AI model Thermalytix algorithm version 3, dated December 2018 was used for the analysis.
Study NCT02189122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bradykinin
Description: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Study NCT03151616 — intervention group
Intervention type: OTHER
Intervention: anticholinergic risk scale
Description: Risk summation scale for grading and studying anticholinergic medication exposure
Study NCT02189122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: Subjects will take Aspirin 81 mg per day for five days.
Study NCT02166411 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myomectomy using barbed sutures
Description: A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . The myometrial edges will be reapproximated in one or two layers (according to the depth of the uterine wound) by using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).
Study NCT02166411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: myomectomy using conventional sutures
Description: A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . Myometrial edges will be re-approximated using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ)
Study NCT01856049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of umbilical cord blood
Description: Cord blood will be processed in the temperate state it was collected to produce a pure, stem cell product identifiable to patients with Hypoplastic Left Heart Syndrome, and will be stored at a frozen state for their potential, future use in a clinical trial.